|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 38/18 | (2006.01) |
| A61K 45/06 | (2006.01) | ||
| A61P 3/06 | (2006.01) | ||
| A61P 3/04 | (2006.01) | ||
| A61P 9/10 | (2006.01) | ||
| A61P 5/50 | (2006.01) | ||
| A61P 9/12 | (2006.01) |
| (11) | Number of the document | 3727423 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18842846.0 |
| Date of filing the European patent application | 2018-12-21 | |
| (97) | Date of publication of the European application | 2020-10-28 |
| (45) | Date of publication and mention of the grant of the patent | 2024-05-22 |
| (46) | Date of publication of the claims translation | 2024-07-10 |
| (86) | Number | PCT/IB2018/060538 |
| Date | 2018-12-21 |
| (87) | Number | WO 2019/123427 |
| Date | 2019-06-27 |
| (30) | Number | Date | Country code |
| 201762609489 P | 2017-12-22 | US |
| (72) |
GOLDFINE, Allison , US
YI, Byungdoo Alexander , US
|
| (73) |
Novartis AG ,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Metabolinių sutrikimų gydymas FGF21 variantais |
| TREATMENT OF METABOLIC DISORDERS WITH FGF21 VARIANTS |
| Payment date | Validity (years) | Amount | |
| 2024-11-22 | 7 | 162.00 EUR |
| 2025-12-21 |